News from sorrento therapeutics, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

May 15, 2015, 12:18 ET

NantWorks acquiert Cynviloq™ pour un montant supérieur à 1,3 milliard de dollars US

-- Un versement initial de plus de 90 millions d'USD et des versements échelonnés de plus de 1,2 milliard d'USD --Sorrento garde la...

May 15, 2015, 10:38 ET

NantWorks verwerft Cynviloq™ voor minimaal $ 1,3 miljard

--Betaling van minimaal $ 90 miljoen vooraf en minimaal $ 1,2 miljard aan mijlpaalbetalingen --Sorrento behoudt optie voor de gezamenlijke...

May 15, 2015, 09:00 ET
Sorrento Therapeutics, Inc.

NantWorks Acquires Cynviloq™ For Up To $1.3+ Billion

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), announced today that NantPharma, founded by Dr. Patrick Soon-Shiong and a member of the...

May 04, 2015, 10:44 ET

Sorrento gibt positive Ergebnisse für TRIBECA™ Zulassungsstudie bekannt

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) freut sich, positive Ergebnisse der vor kurzem analysierten pharmakokinetischen (PK) Daten aus seiner...

May 04, 2015, 09:46 ET

Sorrento annonce des résultats positifs pour son étude d'homologation TRIBECA™

Sorrento Therapeutics, Inc. (NASDAQ : SRNE) est heureuse d'annoncer des résultats positifs des données de pharmacocinétique...

May 04, 2015, 09:31 ET

Sorrento kondigt een positief resultaat aan van het TRIBECA™-registratieonderzoek

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is verheugd met de bekendmaking van het positieve resultaat van de onlangs geanalyseerde...

May 04, 2015, 09:00 ET
Sorrento Therapeutics, Inc.

Sorrento Announces Positive TRIBECA™ Registrational Study Results

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is pleased to announce positive results from recently analyzed pharmacokinetic (PK) data from its...

Apr 30, 2015, 16:32 ET
Sorrento Therapeutics, Inc.

Sorrento Announces the Appointments of David H. Deming to the Board of Directors and Mark W. Durand as Chief Financial Officer

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated...

Apr 18, 2015, 16:32 ET
Apr 13, 2015, 09:00 ET
Sorrento Therapeutics, Inc.

Sorrento to Present at Jefferies 2015 Immuno-Oncology Summit

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated...

Mar 30, 2015, 09:00 ET
Sorrento Therapeutics, Inc.

Sorrento Announces Appointment Of George Ng As EVP & Chief Legal Officer

Sorrento Therapeutics, Inc. (Nasdaq: SRNE) announced today the appointment of George K. Ng to the position of Executive Vice President & Chief...

Mar 17, 2015, 07:20 ET

NantWorks et Sorrento annoncent une deuxième collaboration mondiale complète sur la découverte et le développement de nouvelles immunothérapies anticancéreuses

- NantCell acquiert les droits exclusifs d'anticorps comprenant les produits CAR-TNK™ et les inhibiteurs des points de contrôle PD-1 et...

Mar 17, 2015, 07:14 ET

NantWorks en Sorrento kondigen tweede brede wereldwijde samenwerking aan in de ontdekking en ontwikkeling van nieuwe immunotherapieën tegen kanker

- NantCell zal exclusieve rechten verwerven op antilichamen waaronder CAR-TNK™ Producten en de checkpointremmers PD-1 en PD-L1...

Mar 16, 2015, 13:56 ET

NantWorks und Sorrento kündigen ihre zweite, umfassende, weltweite Kooperation bei der Entdeckung und Entwicklung neuartiger Immunotherapien gegen Krebs an

- NantCell erwirbt die exklusiven Rechte an Antikörpern, wie den CAR-TNK™ Produkten und den Checkpoint-Inhibitoren PD-1 und PD-L1...

Mar 16, 2015, 09:00 ET
Sorrento Therapeutics, Inc.

NantWorks And Sorrento Announce Second Comprehensive Global Collaboration On Discovery And Development Of Novel Anti-Cancer Immunotherapies

 NantWorks, Inc. and Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), announced today that they have entered into a...

Feb 23, 2015, 09:00 ET
Sorrento Therapeutics, Inc.

Sorrento to Present at Cowen and Company's 35th Annual Health Care Conference

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), an oncology company developing new treatments for cancer and associated...

Feb 05, 2015, 09:00 ET
Sorrento Therapeutics, Inc.

Sorrento to Present at the 17th Annual BIO CEO & Investor Conference

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated...

Feb 02, 2015, 09:00 ET
Sorrento Therapeutics, Inc.

Sorrento Announces Retention of Glen Sato to Provide Strategic Support

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced...

Jan 28, 2015, 14:41 ET

Sorrento kondigt afronding aan van deelname aan het Cynviloq™ TRIBECA™ registratieonderzoek

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), een oncologiebedrijf dat nieuwe behandelingen voor kanker en aanverwante pijn ontwikkelt,...

Jan 28, 2015, 12:00 ET

Sorrento annonce la fin du recrutement dans l'étude TRIBECA™ d'enregistrement Cynviloq™

Sorrento Therapeutics, Inc. (NASDAQ : SRNE ; Sorrento), la société d'oncologie qui développent de nouveaux traitements...